Sept 23 (Reuters) - Biohaven ( BHVN ) said on Monday it
had met the main goal in a study evaluating its treatment in
patients with an inherited disease that mainly affects the
brain.
(Reporting by Christy Santhosh; Editing by Anil D'Silva)